Fig. 3
From: Screening of the FDA-approved drug library identifies CCL17 inhibitors that block arthritic pain
Fluoxetine, ractopamine, ponesimod, terbutaline and etravirine down-regulate GM-CSF-induced STAT5 activity and IRF4 expression in BMDMs. BMDMs were pre-treated with fluoxetine, ractopamine, ponesimod, terbutaline and etravirine (10 µM) for 30 min and treated with GM-CSF (20 ng/mL) for 16 h. (A) Irf4 and (B) Irf5 mRNA expression (qPCR) were determined. (C,D) Whole cell lysates were subjected to Western blotting with anti-pSTAT5, anti-tSTAT5, anti-IRF4, and anti-β-actin antibodies. (C) A representative blot is shown. (D) The quantified data are graphed as scatterplots with bars, indicating mean ± SEM. P values were obtained using one-way ANOVA with Tukey post-test (n = 4), where *p < 0.05, **< 0.01. ND, not detected. Original Western blots are presented in Supplementary Fig. 3.
